Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (39): 7285-7290.doi: 10.3969/j.issn.1673-8225.2010.39.016

Previous Articles     Next Articles

Platelet function and tirofiban treatment in patients with non-ST-segment elevation acute coronary syndromes following stenting

Liang Hai-feng1, Yang Ming1, Cui Jian-ying2, Han Ling1, Gao Kang1, Zhao Yan1, Chen Ping1   

  1. 1 Cardiology Center, 2 Laboratory of Internal Medicine, Fuxing Hospital of Capital Medical University, Beijing  100038, China
  • Online:2010-09-24 Published:2010-09-24
  • Contact: Yang Ming, Doctor, Professor, Chief physician, Cardiology Center, Fuxing Hospital of Capital Medical University, Beijing 100038, China
  • About author:Liang Hai-feng★, Master, Associate chief physician, Cardiology Center, Fuxing Hospital of Capital Medical University, Beijing 100038, China Lianghaifeng_dty@126.com

PDF

352

Abstract:

BACKGROUND: Individualized anti platelet therapy remains controversial in perioperative period of percutaneous coronary intervention (PCI). Moreover, the combination administration for anti platelet, administration time and duration are poorly understood.
OBJECTIVE: To test the influence of stent planting on the platelet activation in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) and the effects of tirofiban.
METHODS: A total of 125 patients were randomly assigned to two groups: tirofiban (n=62): clopidogrel +aspirin+ tirofiban; control group (n=63): clopidogrel +aspirin. Both groups were treated with PCI. The maximum platelet aggregation rates (mPAR) induced by arachidonic acid (AA), platelet activation marker CD62p were measured before and 6, 24, hours and 7 days post-stenting. Moreover, clinical endpoint cases were monitored within 30 days after PCI.
RESULTS AND CONCLUSION: After PCI 6 hours, mPAR and CD62p were reduced significantly in tirofiban group compared with pre-PCI operation and control group (P < 0.01) and that in control group were significantly higher than pre-PCI (P < 0.01). No significant differences were observed in the mPAR and the CD62p in two groups at post-PCI 24 hours (P > 0.05). After PCI 7 days, mPAR was reduced in tirofiban group compared with pre-PCI operation (P < 0.05). The incidence of clinical ischemic event in tirofiban group was significantly lower than the control group after PCI 30 days (P < 0.05), but no significant differences were detected in clinical bleeding event (P > 0.05). After PCI 6 hours, the platelet function is activated. On the basis of double anti-platelet treatment (clopidogrel +aspirin), the platelet function is further inhibited by tirofiban in patients with NSTE-ACS after PCI.

CLC Number: